Ocrelizumab and Fatigue: What Patients Report
Ocrelizumab is dosed every six months. Users tracking energy through the infusion cycle report a recognizable pattern in the days and weeks after each dose.
Key points
- •Infusion-day and next-day fatigue are common and usually resolve within 48 hours.
- •A second, milder dip is often reported 7–14 days post-infusion.
- •Energy stability in months 3–5 is the typical target zone.
- •Individual patterns vary — cohort averages are a starting point, not a prescription.
What the data shows
In cohort data, the median PROMIS Fatigue-MS 8a score dips 2–4 T-score points in the first 72 hours post-infusion and returns to baseline by week 2.
What to try
- 01Schedule light weeks around infusion days 1–3.
- 02Plan your most demanding personal commitments in months 3–5 of the cycle.
- 03Bring your energy trend to your infusion visit — it's the most useful signal for cadence discussions.
- 04Never adjust dosing without your neurology team.
Frequently asked
Is fatigue after ocrelizumab a sign the medication isn't working?
No. Transient fatigue post-infusion is a well-documented, unrelated infusion-reaction pattern. Efficacy is judged over months and MRI, not the day-of-fatigue signal.
Should I move my infusion date based on fatigue?
Small shifts (a week or two) are common and safe with your team's guidance. Larger shifts are a clinical decision, not a scheduling one.
See your own pattern.
A 60-second daily check-in surfaces the correlations that matter for you — not the average user.
Try Myelina Health freeRelated
Educational content, not medical advice. Always discuss changes to your treatment or routine with your neurology team.